Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget. 2015 Oct 20; 6(32):33290-305.
View in:
PubMed
subject areas
Animals
Animals
Antineoplastic Agents
Antineoplastic Agents
Arachidonate 5-Lipoxygenase
Arachidonate 5-Lipoxygenase
Carcinoma, Pancreatic Ductal
Carcinoma, Pancreatic Ductal
Cyclooxygenase 2
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase 2 Inhibitors
Drug Synergism
Drug Synergism
ErbB Receptors
ErbB Receptors
Female
Female
Lipoxygenase Inhibitors
Lipoxygenase Inhibitors
Male
Male
Mice
Mice
Mice, Inbred C57BL
Mice, Inbred C57BL
Mice, Transgenic
Mice, Transgenic
Pancreatic Neoplasms
Pancreatic Neoplasms
Pyrroles
Pyrroles
Quinazolines
Quinazolines
Signal Transduction
Signal Transduction
authors with profiles
Venkateshwar Madka